Constrictive pericarditis is a medical condition characterized by the inflammation and fibrosis of the pericardium, the thin sac surrounding the heart. This condition leads to the thickening and stiffening of the pericardial layers, restricting the heart's ability to expand and fill with blood during diastole. As a result, the heart's pumping efficiency is compromised, leading to symptoms such as fatigue, shortness of breath, and fluid retention. Constrictive pericarditis can be caused by various factors, including viral or bacterial infections, previous heart surgery, or chronic inflammatory conditions. Diagnosis often involves a combination of clinical evaluation, imaging studies such as echocardiography, and sometimes invasive procedures like cardiac catheterization. Treatment typically involves addressing the underlying cause, along with managing symptoms through medications or, in severe cases, surgical intervention to remove or repair the constricting pericardium. Early detection and appropriate management are crucial for improving outcomes and preventing complications in individuals with constrictive pericarditis.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India